Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-2; TIL-138I TCR transduced T-cells
- Indications Malignant melanoma
- Focus Adverse reactions
- 30 Oct 2020 Biomarkers information updated
- 24 Jul 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.